Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 358

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 358
---
 operations and logistics requirements, and unmet market needs that we have identified. We have a track record that has allowed us to achieve product market fit with our services. As such, we believe OmnigenicsAI’s products can play a pivotal role in revolutionizing health management. • Adoption: we anticipate that, as we enhance our customer experience and the industry develops, more consumers will desire genetic tests and physicians will be open and more willing to incorporate genetic information into their practice. This is especially true in encouraging adoption among non -geneticexperts, who are often the initial contact for customers and patients in a health journey. Further, we expect to advance adoption of our products and services by publishing research and providing educational support, thus generating awareness on the benefits of genetic testing. • Partners: we are committed to commercializing our products through the Americas, fostering a range of partnerships with laboratories, providers, payers, among other key market players. We will continue to bolster our existing partnerships while also exploring new ones to enter new markets and develop new products. These include diagnostic laboratories through the strategic consortium, pharmaceutical companies, biopharma partners, healthcare service providers and health systems, who face significant barriers such as lack of technology, lack of localized genomic databases, and expertise. • Lower cost: as we plan on continuing to expand our business and network, we expect to reduce our costs while continuing our pursuit of accessible prices to further increase our addressable market. We are poised to benefit from the ongoing reduction in genetic sequencing and data processing costs, which have decreased substantially in recent years and continue to trend downward. This decline has been driven by advancements in sequencing technology and bioinformatics, therefore making genetic testing more affordable and accessible to a broader population. According to industry reports, the cost of sequencing as decreased approximately 21% over the past ten years. We believe this downward trend increases the potential reach and penetration of our services in sizeable and underserved populations in a range of geographies. • Sustainable and inclusive growth: we are committed to working with all of our partners to ensure that genetic testing is continuously improved. This is critical in the context of growing demand and mass adoption of these technologies. Likewise, we will focus on making our products increasingly affordable and broadly available. Business Development Overview We are focused on making comprehensive, high -qualitygenetic information more accessible and instrumental to the healthcare ecosystem and directly to the general population, to revolutionize health management. As we develop our products and grow, we expect to expand and evolve in the near future in the stages described